Cytosorbents (NASDAQ:CTSO) Issues Earnings Results, Beats Estimates By $0.42 EPS

Cytosorbents (NASDAQ:CTSO) posted its earnings results on Thursday. The medical research company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.42, FiscalAI reports. Cytosorbents had a negative net margin of 48.94% and a negative return on equity of 431.65%. The business had revenue of $9.73 million for the quarter, compared to the consensus estimate of $9.90 million.

Here are the key takeaways from Cytosorbents’ conference call:

• CytoSorbents reported third-quarter operating cash flow of about $43,000, excluding restructuring payments, meeting its stated breakeven objective. Product gross margin rose to 75% and adjusted EBITDA loss narrowed to about $284,000, though management cautioned that cash flow may fluctuate and breakeven is not guaranteed every quarter.
• Revenue increased 3% year over year to $9.7 million, with distributor and partner sales up 18%, but sales in Germany fell about 20%–21% amid reduced sales-force coverage. The company has begun rebuilding its German team and plans further hires, while targeting sustainable product gross margins in the mid-70% range.
• The company is preparing an expanded DrugSorb-ATR De Novo submission for ticagrelor use in early 2027, pending completion of an animal study and further regulatory work; it also expects a separate DOAC pathway submission in 2027. Management cited encouraging clinical evidence and FDA discussions, but U.S. authorization and timing remain uncertain.
• CytoSorbents is exploring non-dilutive funding, partnerships, licensing, and other strategic options for HemoDefend-BGA, a blood-product filtration technology, aiming to unlock value without significant investment from core operations. No specific deal or funding outcome was announced.
• The company ended the quarter with $5.7 million in cash, cash equivalents, and restricted cash, and said it is working to meet its remaining Nasdaq listing requirement and restructure its debt by year-end. Its ability to complete those efforts and finance the business remains uncertain.

Cytosorbents Trading Down 9.0%

CTSO traded down $0.48 during trading on Friday, reaching $4.88. 6,516 shares of the stock traded hands, compared to its average volume of 14,471. The company has a quick ratio of 0.50, a current ratio of 0.66 and a debt-to-equity ratio of 4.70. The stock’s 50-day moving average is $4.92 and its 200 day moving average is $9.12. Cytosorbents has a 12 month low of $2.84 and a 12 month high of $17.00. The stock has a market capitalization of $15.39 million, a PE ratio of -0.84 and a beta of 1.49.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on CTSO. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cytosorbents in a research note on Friday, October 2nd. WBB Securities began coverage on shares of Cytosorbents in a report on Wednesday, October 21st. They set a “speculative buy” rating and a $9.50 price target on the stock. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Cytosorbents has a consensus rating of “Hold” and a consensus price target of $74.83.

Insider Buying and Selling

In related news, CEO Phillip Chan acquired 200,000 shares of Cytosorbents stock in a transaction dated Friday, September 4th. The stock was bought at an average price of $0.35 per share, with a total value of $70,000.00. Following the transaction, the chief executive officer directly owned 1,944,432 shares in the company, valued at $680,551.20. This represents a 11.47% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. 7.80% of the stock is owned by corporate insiders.

About Cytosorbents

CytoSorbents Corporation is a medical device and healthcare company that develops blood purification technologies designed to remove harmful substances from the bloodstream. Its products use proprietary, porous polymer adsorbent materials that can bind and remove cytokines, inflammatory mediators, drugs, and other molecules during extracorporeal blood treatment. The company’s principal product is CytoSorb, an extracorporeal cytokine adsorber used in critical care and cardiac surgery applications.